Atosiban

Atosiban (1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin; CAS 90779-69-4; molecular formula C43H67N11O12S2; molecular weight 994.19 g/mol) is a synthetic cyclic nonapeptide analogue of oxytocin that functions as a competitive antagonist at the oxytocin receptor and at the vasopressin V1a receptor, developed by Ferring Pharmaceuticals in Sweden and first reported in the literature by Melin et al. in 1986 [1]. The compound is the only oxytocin receptor antagonist approved for clinical tocolytic use, registered in the European Union since January 2000 under the trade name Tractocile and subsequently approved in approximately 67 countries for the acute management of preterm labor in pregnant women between 24 and 33 completed weeks of gestation. Atosiban is not approved by the United States Food and Drug Administration or in Japan; the absence of United States registration reflects Ferring's assessment that the FDA requirement for placebo-controlled trials in United States patients would be ethically untenable rather than a formal regulatory rejection on efficacy or safety grounds [2]. At the molecular level, atosiban inhibits oxytocin-mediated activation of the Gq/phospholipase C/inositol 1,4,5-trisphosphate signaling cascade in myometrial cells, reducing intracellular calcium release from the sarcoplasmic reticulum and diminishing calcium influx through voltage-gated channels, thereby suppressing uterine smooth muscle contraction [3, 4]. The compound additionally suppresses oxytocin-mediated prostaglandin E2 and prostaglandin F2-alpha release from decidual tissue, a secondary mechanism that contributes to the tocolytic effect. Receptor binding studies report moderate affinity for the oxytocin receptor (Ki approximately 397 nmol/L) and high affinity for the vasopressin V1a receptor (Ki approximately 4.7 nmol/L), with negligible affinity at the V1b and V2 vasopressin receptor subtypes [5]. The onset of uterine quiescence after intravenous administration is rapid, with significant reduction in contraction frequency within 10 minutes. Pharmacokinetics are characterized by an initial half-life of 0.21 hours and a terminal half-life of 1.7 hours after intravenous infusion, a volume of distribution of 18.3 liters, plasma protein binding of 46 to 48 percent in pregnant women, and predominantly peptidase-mediated metabolism that is independent of the cytochrome P450 system [6]. The standard clinical dosing regimen comprises a 6.75 mg intravenous bolus followed by a loading infusion of 300 micrograms per minute for 3 hours and a maintenance infusion of 100 micrograms per minute for up to 45 hours, with total treatment not exceeding 48 hours and total dose not exceeding 330.75 mg. Phase III clinical trials demonstrated that 59.6 percent of atosiban-treated women remained undelivered without alternative tocolysis at 7 days compared to 47.7 percent in the beta-agonist comparator arm, with maternal cardiovascular adverse events occurring approximately 10-fold less frequently in the atosiban group (8.3 percent versus 81.2 percent) [7, 8]. The compound is well tolerated; nausea is the most common adverse event at 14 percent, and no serious maternal safety signals have been identified across more than 156,000 treatment cycles in postmarketing surveillance through 2005. A secondary research application in assisted reproduction has emerged from the observation that atosiban-mediated reduction in uterine contractility during embryo transfer may improve implantation rates in in vitro fertilization, with meta-analyses reporting significantly higher clinical pregnancy rates in atosiban-treated groups compared to controls [9, 10]. This monograph documents the chemistry, synthesis, and peptide pharmacology of atosiban; the oxytocin receptor and vasopressin V1a receptor antagonism in molecular and functional detail; the comprehensive pharmacokinetic record; the clinical evidence base across tocolytic and assisted reproduction indications; sourcing and quality verification considerations for research-grade material; reconstitution and handling protocols; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five alternative tocolytic agents (nifedipine, ritodrine, indomethacin, magnesium sulfate, terbutaline) against atosiban on five competency standards.